Changing Lives Through Research

On the Job
Jamie Jay Rothstein, RN, CCRC
As Clinical Research Nurse and the
Project Manager for the Department
of Surgery, Jamie Jay Rothstein builds
systems for implementing and managing
all aspects of the Department’s clinical
trials – from protocol development to
fiscal management. She also guides the
Department’s research coordinators,
interacting with them regularly for ongoing
education and training.
Before joining Jefferson in July 2013,
Rothstein created, developed and managed
a research department of 10 physicians.
Through strategic planning, analysis,
business plan development, quality and
performance improvement, the department
grew to a staff of several coordinators. She
says that while she enjoyed the position,
she jumped at the chance to move from
pharmaceutical to academic research.

The impressive pancreatic cancer research team at Jefferson, led by Jonathan Brody, PhD, and surgeon
Jordan Winter, MD, FACS, recently received a $100,000 donor-funded grant for two promising studies.

Innovative Projects Explore
Metabolism, Chemotherapy
Resistance in Pancreatic
Cancer Cells
A generous contribution via the Gail
V. Coleman-Kenneth M. Bruntel
Charitable Grant Fund (see “Those
Who Give” on p. 4) has enabled
Jordan M. Winter, MD, FACS, Associate
Professor of Surgery, and his team
to initiate two innovative studies in
pancreatic cancer. Here, Dr. Winter
provides an overview of the purpose –
and potential impact – of each project.

Studying Cancer
Cell Metabolism
As Dr. Winter explains, metabolism is
a fundamental biologic process for
the viability of any cell – including
cancer cells. “If you can find a way
to impair that biology, you have an
opportunity to treat cancer by killing
those cells,” he says.
The challenge: Metabolism in cancer
cells isn’t the same as in healthy
cells. In pancreatic cancer cells, a
protein called HuR appears to be an
important regulator of metabolism –
pancreatic cancer’s “secret weapon”
in withstanding austere conditions.
“Even with very low levels of oxygen
and other nutrients, such as glucose
and glutamine, pancreatic cancer
cells not only survive but thrive,” Dr.
Winter says. Prior work by Dr. Winter
and Director of the Division of Surgical
Research, Jonathan R. Brody, PhD, has
focused on the role of HuR as a prosurvival protein. In other words, remove
HuR and pancreatic cancer cells die.
Thanks to the Coleman-Bruntel
contribution, Dr. Winter and his
laboratory team will be conducting a

“I love having the opportunity to work with
the physicians and research coordinators
at Jefferson,” she says. “Their passion for
research – and compassion for patients –
is unparalleled.”

sophisticated metabolic experiment to
better understand the “how” and “why”
of HuR. They will do so by mapping
the flow of carbon through metabolic
pathways in cells with and without HuR.
“Along with genetics and immunology,
cancer cell metabolism is one of the
hottest fields in cancer biology,” Dr.
Winter notes. “This experiment is the
first time anyone has examined how
HuR affects metabolic pathways. It’s
also the deepest exploration into how
RNA biology plays a role in cancer
cell metabolism.”

Rothstein has been a nurse since 1991,
when she was the first Graduate Nurse
hired into the Cardiac Intensive Care Unit
at the Children’s Hospital of Philadelphia.
By 1995, she was serving as Primary Nurse
and Clinical Research Nurse Coordinator
at CHOP.
Over the past two decades, she has worked
in a variety of clinical nursing fields and

“About half of these patients have some
benefit, with the tumor remaining
stable or shrinking. Eventually, though,
the biology of every tumor adjusts to
develop resistance.”

“Analysis of the pre-treatment and postprogression biopsies will provide us with
clues as to how the cancer evolves to
gain resistance to the chemotherapy.”
Understanding
Chemotherapy Resistance

The team wants to understand how the
tumor adapts at the genetic level.

The Coleman-Bruntel gift has also
enabled Dr. Winter and his team to take
on a second, more translational study –
in other words, work that will be more
directly applicable in patient care. This
one aims to enhance understanding
of the mechanisms of chemotherapy
resistance in pancreatic cancer.

For five to 10 patients, the team will first
take a blood sample to obtain germline
DNA to sequence (a laboratory process
used to find mutations that may cause
disease). Any mutations inherited from
the germ cells (egg cell and sperm
cell) of the patient’s parents will be
found in this germline sequence. This
will give the researchers a baseline for
comparison.

“We’re studying patients with advanced
pancreatic cancer who receive the
most common treatment for stage
4 cancer, which is FOLFIRINOX and
GEM/ABRAX,” explains Dr. Winter.

clinical research positions, including serving
as a nurse educator for the OR in the Same
Day Surgery Unit at several hospitals and
surgical centers. In addition to being a
Certified Clinical Research Coordinator, she
holds certifications in Good Clinical Practice
from the National Institutes of Health and
is a member of SOCRA (Society of Clinical
Research Associates) and ACRP (Association
of Clinical Research Professionals).
Rothstein lauds the quality of research
underway at Jefferson: “We’re doing
innovative and groundbreaking work, such
as studies of immunotherapy for specific
kinds of cancer and growth of cell lines.
The physicians are committed to the
studies’ success.”
She lives with her husband in Cherry Hill,
NJ, and enjoys being a mother to two
daughters—and three Newfoundland dogs.

extract DNA and sequence the genome
of the cancer before treatment. Finally,
they will take a second biopsy during
treatment once the tumor stops
responding to chemotherapy and
begins progressing. In other words,
they will re-sample the tumor only
after the biology of the cancer has
changed – likely as a function of
new mutations.
“Analysis of the pre-treatment and
post-progression biopsies will provide
us with clues as to how the cancer
evolves to gain resistance to the
chemotherapy,” Dr. Winter explains.
“A better understanding of which
genes or pathways change may help
in better targeting those pathways and,
ultimately, in improving chemotherapy.”
Dr. Winter is quick to note that this
is the first pilot of its kind and was
made possible solely through the
Coleman-Bruntel gift. It’s already
serving as a springboard for further
funding – and will likely be the first in
a series of studies into chemotherapy
resistance.

Second, the team will take a tumor
biopsy prior to starting chemotherapy.
They will grow the cell line in the lab,
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